Facial scar remodeling with fractional CO2 laser plus PDRN versus CO2 laser alone

Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With Polydeoxyribonucleotide (PDRN) Versus Fractional CO₂ Laser: A Randomized Controlled Clinical Study

This test checks whether adding PDRN injections to fractional CO2 laser treatment helps adults (18–50) with recent facial surgical or cut scars (1–6 months old) heal faster and look better than laser alone.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Ages: 18 Years to 50 Years
• Sex: All
• Sponsor: Misr University for Science and Technology (other)
• Locations: 1 site (Giza)
• Trial ID: NCT07472192 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional study compares two approaches for remodeling maxillofacial scars: fractional CO2 laser alone versus fractional CO2 laser combined with polydeoxyribonucleotide (PDRN). Eligible adults receive one of the two treatment approaches and are followed for clinical signs of scar improvement, healing speed, and safety outcomes. The study excludes pregnant or breastfeeding people, anyone allergic to PDRN, and those on medications or with conditions that impair wound healing. Outcomes are measured by clinical assessments and safety monitoring during scheduled in-person visits at the study site.

Who should consider this trial

Good fit: Adults aged 18–50 with recent (1–6 month) facial surgical or cut scars who can attend in-person visits and provide informed consent.

Not a fit: People who are pregnant or breastfeeding, allergic to PDRN, taking medications that affect wound healing, or with uncontrolled medical conditions are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, combining PDRN with fractional CO2 laser could speed healing and improve the appearance of recent facial scars compared with laser alone.

How similar studies have performed: Fractional CO2 laser is an established scar treatment and small studies suggest PDRN may aid wound healing, but evidence for the combined approach is still limited.

Eligibility criteria

Inclusion Criteria:

* Age Limitations: Participants must be between 18 and 50 years of age.
* Recently cut wounds or surgical scars from about (1-6 months).
* Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.

Exclusion Criteria:

* Pregnancy or breastfeeding at the time of study.
* Known allergy to PDRN.
* Medication use that could affect wound healing or inflammation, such as:

  * Isotretinoin.
  * Anticancer drugs.
  * High-dose corticosteroids.
  * Anticoagulants.
* Uncontrolled medical diseases (e.g., unstable diabetes, cardiac conditions).

Where this trial is running

Giza

• Misr University for Science and Technology — Giza, Egypt (RECRUITING)

Study contacts

• Study coordinator: Omnia Tarek Hosni

Conditions: Facial Scarring